Retrospective analysis of therapeutic efficacy of haploidentical allogeneic hematopoietic stem cell transplantation for severe aplastic anemia.
10.7534/j.issn.1009-2137.2014.05.033
- Author:
Yuan ZHANG
1
;
Xiao-Dong LIU
1
;
Xue-Peng HE
1
;
Jing-Xin LOU
1
;
Zhi GUO
1
;
Hui-Ren CHEN
2
Author Information
1. Department of Hematology, General Hospitol of Beijing Military Command, Chinese PLA, Beijing 100700, China.
2. Department of Hematology, General Hospitol of Beijing Military Command, Chinese PLA, Beijing 100700, China. E-mail: chenhui-ren@medmail.com.cn.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Allografts;
Anemia, Aplastic;
diagnosis;
therapy;
Antilymphocyte Serum;
Cyclosporine;
Graft vs Host Disease;
Haploidy;
Hematopoietic Stem Cell Transplantation;
Humans;
Retrospective Studies;
Siblings;
Survival Rate;
Tissue Donors;
Transplantation Conditioning;
Vidarabine;
analogs & derivatives
- From:
Journal of Experimental Hematology
2014;22(5):1354-1358
- CountryChina
- Language:Chinese
-
Abstract:
This study was purposed to investigate the therapeutic efficacy of haploidentical allogeneic hemopoietic stem cell transplantation (allo-HSCT) for severe aplastic anemia (SAA), and evaluate the safety of this treatment by retrospective analysis. A total of 21 patients with SAA (13 cases of SAA-I, 8 cases of SAA-II) were treated with haploidentical allo-HSCT. Donors were the relatives of the patients (12 were the parents, 9 were the siblings). The conditioning regimen contained cyclophosphamide, fludarabine and antithymocyte globulin. Methylaminopterin, mycophenolate mofetil and cyclosporin A were used for preventing graft versus host disease (GVHD). The chimerism rate was monitored periodically after successful graft. The long survival rate, incidence and severity of complication, such as GVHD, infection, and so on were analyzed. The results showed that 15 out of 21 patients were survived for 16 (3-46) months, survival rate was 71.4%. Graft tailure happened in one case who died of mycetes septicemia at 43 days after allo-HSCT. Two patients died of pulmonary infection at 6 days and 10 days respectively after transplantation. Rejection happened in one case at 3 months who died of pulmonary infection at 17 days after the second transplantation with the same donor. Two patients died of IV grade intestinal GVHD at 35 days and 52 days. GVHD occurred in 14 of 21 patients, the accumulative incidence was 66.7%, 5 cases of them were severe. It is concluded that the therapeutic efficacy of haploidentical allo-HSCT is effective for SAA and with slighter complications.
